The TKT gene is located on chromosome 3 at position 3p21.1 . It encodes a homodimeric enzyme with two active sites situated at the monomer contact surfaces . In addition to TKT, there are two other transketolase-like proteins in humans: TKTL1 and TKTL2, located on the X chromosome at Xq28 and chromosome 4 at 4q32.2, respectively . These proteins share structural similarities with TKT and are believed to be functional transketolases .
Transketolase is pivotal in generating sugar phosphates necessary for intracellular nucleotide metabolism and the production of nicotinamide adenine dinucleotide phosphate (NADPH), a crucial reducing agent and antioxidant . The enzyme’s activity is vital for maintaining cellular redox balance and supporting anabolic reactions.
Altered TKT functionality has been implicated in various diseases, including diabetes and cancer . For instance, hyperglycemic individuals often exhibit reduced TKT activity, which can be ameliorated by thiamine treatment, suggesting potential therapeutic applications for type 2 diabetes . Additionally, TKT activity and its nuclear localization have been linked to the progression of hepatocellular carcinoma (HCC), highlighting its role in both metabolic and non-metabolic pathways in cancer development .
Recombinant transketolase is produced using genetic engineering techniques to express the human TKT gene in suitable host cells, such as bacteria or yeast. This allows for the large-scale production of the enzyme for research and therapeutic purposes. Recombinant TKT retains the functional properties of the native enzyme, making it a valuable tool for studying its role in cellular metabolism and disease.